LEADER 00895nam0-22003011i-450- 001 990001226500403321 035 $a000122650 035 $aFED01000122650 035 $a(Aleph)000122650FED01 035 $a000122650 100 $a20000920d1862----km-y0itay50------ba 101 0 $aeng 200 1 $aTraitè èlèmentaire de calcul diffèrentiel et de calcul intègral$fS.F. Lacroix. 205 $a6. ed. - 210 $aParis$cMallet-Bachelier$d1862. 300 $aTome 2. 610 0 $aCalcolo differenziale 610 0 $aCalcolo integrale 676 $a515.1 700 1$aLacroix,$bSylvestre François$f<1765-1843>$0349188 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001226500403321 952 $a1-B-12$b01081$fMA1 959 $aMA1 996 $aTraitè èlèmentaire de calcul diffèrentiel et de calcul intègral$9381920 997 $aUNINA DB $aING01 LEADER 01234nam a22002651i 4500 001 991003422999707536 005 20040414224017.0 008 040802s1922 fr a||||||||||||||||fre 035 $ab13073485-39ule_inst 035 $aARCHE-102609$9ExL 040 $aBiblioteca Interfacoltà$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l. 082 04$a848 100 1 $aLa Boétie, Etienne :$cde$0413975 245 10$aDiscours de la servitude volontaire :$bsuivi du Mémoire touchant l'Édit de janvier 1562 (inédit) et d'une Lettre de m. le conseiller de Montaigne /$cLa Boétie ; introduction et notes de Paul Bonnefon ; orné d'un portrait gravé sur bois par Ouvré 260 $aParis :$bBossard,$c1922 300 $a214 p. :$bill. ;$c19 cm 440 0$aCollection des chefs-d'oeuvre méconnus ;$v30 700 1 $aMontaigne, Michel Eyquem :$cde$d<1533-1592> 700 1 $aBonnefon, Paul 907 $a.b13073485$b02-04-14$c05-08-04 912 $a991003422999707536 945 $aLE002 Fondo Giudici D 1007$g1$i2002000221407$lle002$nC. 1$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i13701253$z05-08-04 996 $aDiscours de la servitude volontaire$914042 997 $aUNISALENTO 998 $ale002$b05-08-04$cm$da $e-$ffre$gfr $h0$i1 LEADER 05281nam 22006374a 450 001 9910830224103321 005 20170815113943.0 010 $a1-281-13531-3 010 $a9786611135317 010 $a0-470-51743-3 010 $a0-470-51744-1 035 $a(CKB)1000000000413971 035 $a(EBL)326413 035 $a(OCoLC)476124182 035 $a(SSID)ssj0000176759 035 $a(PQKBManifestationID)11170150 035 $a(PQKBTitleCode)TC0000176759 035 $a(PQKBWorkID)10206033 035 $a(PQKB)10010364 035 $a(MiAaPQ)EBC326413 035 $a(PPN)188664904 035 $a(EXLCZ)991000000000413971 100 $a20070604d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aIminosugars$b[electronic resource] $efrom synthesis to therapeutic applications /$feditors, Philippe Compain and Olivier R. Martin 210 $aChichester, West Sussex, England ;$aHoboken, NJ, USA $cJ. Wiley$dc2007 215 $a1 online resource (487 p.) 300 $aDescription based upon print version of record. 311 $a0-470-03391-6 320 $aIncludes bibliographical references and index. 327 $aIminosugars; Contents; Foreword; Preface; List of contributors; 1 Iminosugars: past, present and future; 2 Naturally occurring iminosugars and related alkaloids: structure, activity and applications; 2.1 Introduction; 2.2 -Glucosidase inhibitors; 2.3 -Glucosidase inhibitors; 2.4 - and -Galactosidase inhibitors; 2.5 -Mannosidase inhibitors; 2.6 Concluding remarks and future prospects; References; 3 General strategies for the synthesis of iminosugars and new approaches towards iminosugar libraries; 3.1 Introduction; 3.2 Monocyclic compounds; 3.3 1-N-Iminosugars; 3.4 Bicyclic compounds 327 $a3.5 Other bicyclic compounds3.6 Iminosugar conjugates; 3.7 Conclusions; References; 4 Iminosugar C-glycosides: synthesis and biological activity; 4.1 Introduction; 4.2 Synthesis of iminosugar C-glycosides; 4.3 Biological activity of iminosugar C-glycosides; 4.4 Conclusion; References; 5 Imino-C-disaccharides and analogues: synthesis and biological activity; 5.1 Introduction; 5.2 Synthesis of imino-C-disaccharides; 5.3 Conformations of imino-C-disaccharides; 5.4 Glycosidase inhibitory activities of imino-C-disaccharides 327 $a5.5 Efficient combinatorial method for the discovery of glycosidase inhibitors5.6 Antitumour activity of new -mannosidase inhibitors; 5.7 Conclusion; References; 6 Isofagomine, noeuromycin and other 1-azasugars, iminosugar-related glycosidase inhibitors; 6.1 Introduction; 6.2 1-Azasugars that are piperidines (isofagomine, noeuromycin, etc.); 6.3 1-Azasugars that are hydrazines; 6.4 1-Azasugars that are oxazines; 6.5 1-Azasugars that are piperidones; 6.6 Sulphur-containing analogues of 1-azasugars; 6.7 Slow inhibition and thermodynamics of binding 327 $a6.8 Are 1-azasugars (and iminosugars) transition state analogues?References; 7 Iminosugar-based glycosyltransferase inhibitors; 7.1 Biological role and structural features of glycosyltransferases; 7.2 Development of inhibitors of glycosyltransferases; 7.3 Conclusion; References; 8 Transition state analogue inhibitors of N-ribosyltransferases; 8.1 Introduction; 8.2 Nucleoside hydrolases; 8.3 Purine nucleoside phosphorylases (PNPs); 8.4 5'-Methylthioadenosine (MTA) nucleosidases and phosphorylases; 8.5 Ricin A-chain; References; 9 Iminosugars as antiviral agents; 9.1 Introduction 327 $a9.2 The relationship between glucosidase inhibition and antiviral action9.3 Fate of viral glycoproteins in glucosidase-inhibited cells; 9.4 Specificity of glucosidase inhibition; 9.5 N-Alkyl DNJs inhibit virus growth by non-glucosidase inhibitory mechanisms - other potential activities of these compounds; 9.6 New directions for improving glucosidase inhibitors as antiviral agents; References; 10 Iminosugars as active-site-specific chaperones for the treatment of lysosomal storage disorders; 10.1 Introduction; 10.2 Degradation of glycosphingolipids 327 $a10.3 Lysosomal enzyme biosynthesis and ER-associated degradation (ERAD) 330 $aIminosugars form undoubtedly the most attractive of carbohydrate mimics reported so far. In these structures, the substitution of the endocyclic oxygen of sugars by a basic nitrogen atom leads to remarkable biological properties and raises many challenges in organic synthesis. Since the discovery of their biological activity as glycosidase inhibitors in the 1970's, these polyvalent molecules have progressively made their way from the laboratory to the clinic. The impressive series of discoveries in the field over the past ten years indicates clearly that it is "a boom time" for iminosugar 606 $aImino sugars$xSynthesis 606 $aImino sugars$xTherapeutic use 615 0$aImino sugars$xSynthesis. 615 0$aImino sugars$xTherapeutic use. 676 $a572.565 676 $a612/.01578 701 $aCompain$b Philippe$01663703 701 $aMartin$b Olivier R$01663704 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830224103321 996 $aIminosugars$94021215 997 $aUNINA